News & Updates

The overall utilization rates of SGLT2 inhibitors have increased among patients with type 2 diabetes (T2D) following the release of the 2022 American Diabetes Association (ADA) guidelines.

A study suggests that in choosing CDK4/6 inhibitors (palbociclib and abemaciclib) for patients with hormone receptor-positive, HER2-negative metastatic/recurrent breast cancer, considerations must be made based on the tolerability and manageability of adverse events (AEs).

Urea is as effective as tolvaptan in the treatment of hyponatremia, with a lower incidence of overcorrection, as shown in a study.

Weight loss interventions help improve some features of polycystic ovary syndrome (PCOS), making it a potential treatment option for women with PCOS, suggests a study.